Overview

The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome

Status:
Unknown status
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of ProAlgaZyme in increasing levels of HDL 'good' cholesterol and decreasing total cholesterol and C-reactive protein in patients with Metabolic Syndrome.
Phase:
N/A
Details
Lead Sponsor:
Health Enhancement Products, Inc.
Collaborator:
MAPS Applied Research Center